<DOC>
	<DOCNO>NCT01234675</DOCNO>
	<brief_summary>Fibromyalgia condition chronic widespread pain , sleep disturbance fatigue . Most patient fibromyalgia complain either non-restorative sleep complaint disturbed sleep due pain . The propose study aim examine effect milnacipran sleep disturbance patient fibromyalgia . The study randomize , double-blind , placebo control , two way crossover PSG study explore effect milnacipran sleep disturbance . Patients receive either milnacipran 50 mg BID match placebo .</brief_summary>
	<brief_title>The Effects Milnacipran Sleep Disturbance Fibromyalgia</brief_title>
	<detailed_description>The sleep disturbance fibromyalgia characterize non-restorative nature , define feel light sleep , independent duration , non-refreshing . As , patient wake morning complain stiffness overall ache body . It well know reciprocal relationship exist sleep pain , sleep disturbance important contributor morbidity fibromyalgia . Milnacipran , selective serotonin norepinephrine receptor inhibitor ( SNRI ) ) , approve FDA management fibromyalgia . Although milnacipran extensively study fibromyalgia patient , objective measure , i.e. , use overnight polysomnography , determine effect sleep . The study mean explore effect milnacipran , versus placebo , sleep patient fibromyalgia measure overnight PSGs . The study also involve important domain fibromyalgia etiology : sleep disturbance , pain , fatigue quality life .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>1 . Men woman least 18 year old . 2 . Diagnosis fibromyalgia 3 . Clinically significant sleep disturbance , define difficulty maintain sleep ( WASO , AI ) least three time per week least one month . 4 . Understand willing cooperate study procedure . 5 . Maintain normal sleep schedule , daytimeawake nighttimesleep schedule , customary bedtime 9 PM midnight , rise time 5 AM 9 AM . 6 . Patients able speak , read , understand English language , able follow study protocol , able sign inform consent . 1 . Subject follow medical condition : â€¢ Liver disease ; blood disorder , autoimmune disease , endocrine , cardiovascular , hypertension , renal , hepatic , gastrointestinal , neurological disorder ; Active peptic ulcer inflammatory bowel disease . 2 . Significant sleep apnea 3 . Periodic Leg Movement RLS 4 . Any form severe Psychiatric illness , moderate severe depression , include significant risk suicide . 5 . Patients uncontrolled glaucoma . 6 . Inability discontinue prohibit medication . 7 . Female childbearing potential use birthcontrol measure ; lactate . 8 . History alcohol , narcotic , benzodiazepine , substance abuse within past one year . 9 . Patient prohibit Medication include limited : Anxiolytics , anticonvulsant , antipsychotic , lithium , barbiturate , antihistamine , monoamine oxidase inhibitor ; medication affect sleep Any prescription counter stimulant Medications contraindicate use milnacipran 10 . Excessive caffeine use , define consumption 500 mg caffeine xanthine , smoke &gt; 1/2 pack/day , alcohol use &gt; 14 units/week . 11 . History allergy milnacipran .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Sleep disorder</keyword>
	<keyword>Forest Laboratories</keyword>
	<keyword>Milnacipran</keyword>
</DOC>